- |||||||||| Cyramza (ramucirumab) / Eli Lilly, icrucumab (IMC-18F1) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: A Study of Ramucirumab or Icrucumab in Colorectal Cancer (clinicaltrials.gov) - Mar 10, 2013 P2, N=156, Active, not recruiting, N=224 --> 0 Recruiting --> Active, not recruiting
- |||||||||| 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial initiation date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 17, 2013 P2, N=43, Recruiting, Recruiting --> Active, not recruiting Initiation date: Sep 2012 --> Feb 2013
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial termination: Neo-Adjuvant FOLFOX for Rectal Carcinoma (clinicaltrials.gov) - Feb 12, 2013 P2, N=2, Terminated, Active, not recruiting --> Recruiting Recruiting --> Terminated; terminated for lack of enrollment
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change: Neo-Adjuvant FOLFOX for Rectal Carcinoma (clinicaltrials.gov) - Feb 12, 2013 P2, N=2, Terminated, Recruiting --> Terminated; terminated for lack of enrollment N=22 --> 2
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Metastases: Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC (clinicaltrials.gov) - Feb 9, 2013 P3, N=390, Active, not recruiting, N=50 --> 16 Recruiting --> Active, not recruiting
- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Surgery, Metastases: ADORE: Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer (clinicaltrials.gov) - Feb 2, 2013 P2, N=320, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Enrollment change, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 31, 2013 P1, N=33, Active, not recruiting, Recruiting --> Active, not recruiting N=60 --> 33
- |||||||||| Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Enrollment closed, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 31, 2013 P1, N=33, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
|